Trial Profile
Retrospective study comparing stroke risk (overall and by severity) between rivaroxaban- and warfarin-initiated non-valvular atrial fibrillation patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- 31 Dec 2019 Results comparing rivaroxaban and warfarin for stroke and all-cause mortality risk reduction in a real-world setting were published in the Stroke
- 18 Mar 2019 Results presented at the 68th Annual Scientific Session of the American College of Cardiology
- 18 Sep 2018 New trial record